5.33
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
Teacher Retirement System of Texas Grows Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.43 Consensus PT from Brokerages - Defense World
When Would Be The Best Time To Buy Cogent Biosciences Inc (NASDAQ: COGT) Stock? - stocksregister.com
21,653 Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) Bought by Quantbot Technologies LP - Defense World
Swiss National Bank Sells 3,000 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
We're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn Rate - Yahoo Finance
Proficio Capital Partners LLC Buys New Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences Announces Multiple Poster Presentations - GlobeNewswire
Cogent Biosciences Announces Multiple Poster Presentations At 2025 American Association For Cancer Research (AACR) Annual Meeting - MarketScreener
Cogent's Cancer Breakthrough: 4 Precision Therapies Target KRAS, HER2, and Drug Resistance - StockTitan
Charles Schwab Investment Management Inc. Boosts Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Bank of New York Mellon Corp Has $2.02 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Is Cogent Biosciences (COGT) Stock A Solid Choice Right Now? - Barchart
Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? - TradingView
Cogent Biosciences (COGT): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
Is Cogent Biosciences, Inc. (COGT) a Best Biotech Stock According to Billionaires? - Insider Monkey
Proficio Capital Partners LLC Invests $93,000 in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Gastrointestinal Stromal Tumor Treatment Market Size Report - openPR
Cogent Biosciences (NASDAQ:COGT) Earns Sector Outperform Rating from Analysts at Scotiabank - Armenian Reporter
Scotiabank Begins Coverage on Cogent Biosciences (NASDAQ:COGT) - Defense World
Scotiabank Initiates Coverage of Cogent Biosciences (COGT) with Sector Outperform Recommendation - Nasdaq
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.00 Average Target Price from Brokerages - Defense World
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference - The Manila Times
Cogent Biosciences initiated with an Outperform at Scotiabank - TipRanks
New York State Common Retirement Fund Has $180,000 Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
When the Price of (COGT) Talks, People Listen - Stock Traders Daily
Buy Rating for Cogent Biosciences Backed by Promising Clinical Trial Results and Market Potential - TipRanks
Q1 EPS Forecast for Cogent Biosciences Increased by Analyst - Defense World
Needham & Company LLC Reiterates Hold Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World
Cogent Biosciences Reports 2024 Financial Results and Clinical Progress - TipRanks
Cogent Biosciences: Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks
Cogent Biosciences Announces SUMMIT Continues to Showcase - GlobeNewswire
Cogent Biosciences Reports 65% Improvement In Symptom Score From Bezuclastinib In NonAdvSM - Nasdaq
Cogent Biosciences announces expanded results from OLE portion of SUMMIT trial - TipRanks
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Yahoo Canada Finance
Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World
Cogent Biosciences: Promising Pipeline and Market Opportunities Justify Buy Rating - TipRanks
Cogent Biosciences (COGT) Surprises Wall Street with Narrower-Than-Expected Q4 Loss - HPBL
Cogent Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cogent Biosciences (COGT) Reports Q4 2024 Net Loss of $67.9 Mill - GuruFocus
Cogent Biosciences, Inc. SEC 10-K Report - TradingView
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Can Cogent's Triple Catalyst Year Transform Rare Disease Treatment? 3 Key Trial Results Coming in 2025 - StockTitan
Cogent Biosciences (COGT) Projected to Post Earnings on Monday - Defense World
Long Term Trading Analysis for (COGT) - Stock Traders Daily
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.9%Time to Sell? - MarketBeat
Leerink Partnrs Has Strong Forecast for COGT FY2025 Earnings - MarketBeat
You might want to take a look at Cogent Biosciences Inc (COGT) now - SETE News
Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Target Price at $14.33 - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.9% – What’s Next? - Defense World
Investing in Cogent Biosciences Inc (COGT) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year? - Nasdaq
Cogent Biosciences (NASDAQ:COGT) Sees Strong Trading VolumeWhat's Next? - MarketBeat
FY2025 Earnings Estimate for COGT Issued By Leerink Partnrs - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.33 Consensus PT from Brokerages - Defense World
Cogent Biosciences Announces Bezuclastinib Poster in - GlobeNewswire
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):